KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.96

Pembrolizumab with trastuzumab and chemotherapy for HER2-positive advanced gastric cancer: health-related quality-of-life analysis from the randomized KEYNOTE-811 trial.

Y Y Janjigian, A Kawazoe, J Xu, S Lonardi, J-P Metges, L S Wyrwicz, L Shen, Y Ostapenko, M Bilici, M A Lowery, A Valderrama, Y Guan, K Li, C-S Shih, S Y Rha

ESMO Open 10(10) 105542

PMID41033280
PMCIDPMC12514504
DOI10.1016/j.esmoop.2025.105542
发表日期2025-10-01
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
已检查 1 张 PubMed Figure,均未识别为 KM 图:Figure 1:生活质量量表图。
摘要

摘要

BACKGROUND: In the primary analysis of the randomized phase III KEYNOTE-811 trial (NCT03615326), pembrolizumab plus trastuzumab and chemotherapy improved progression-free survival and overall survival versus placebo plus trastuzumab and chemotherapy in participants with previously untreated human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer. PATIENTS AND METHODS: Overall, 698 participants were randomly assigned (1 : 1) to pembrolizumab 200 mg or placebo every 3 weeks, both with trastuzumab and chemotherapy. We report prespecified exploratory patient-reported outcomes (PROs), including change from baseline, time to deterioration (TTD), and overall improvement/stability rate assessed in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) scales/items, EORTC Quality of Life Questionnaire-Stomach 22 pain scale, and EuroQoL 5-dimension 5-level questionnaire visual analog scale. RESULTS: The PRO population comprised 685 participants. At baseline, the rates of compliance and completion for all PRO questionnaires and for both treatment groups were >92%; at week 24, the rates were >80% and >55%, respectively. No between-group differences were observed from baseline to week 24 for the QLQ-C30 global health status/quality of life (GHS/QoL) scale [least squares mean (LSM) difference -1.16; 95% confidence interval (CI) -4.23 to 1.91] and EQ VAS (LSM difference, -0.69; 95% CI -3.06 to 1.68). Median TTD was not reached. A similar proportion of participants in each treatment group had improved and/or stable scores in the QLQ-C30 GHS/QoL scale (pembrolizumab group 71.9%; placebo group 71.5%). Findings were similar for all other prespecified scales/items. CONCLUSIONS: While improving clinical outcomes, the addition of pembrolizumab to trastuzumab and chemotherapy did not negatively impact health-related quality of life during treatment, supporting the use of pembrolizumab plus trastuzumab and chemotherapy for first-line treatment of HER2-positive advanced gastric cancer.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1 LSM score change from baseline to week 24 for EORTC QLQ-C30 GHS/QoL and physical functioning subscale, EORTC QLQ-C30 symptom, and EORTC QLQ-STO22 pain subscales in the PRO population. CI, confidence interval; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30; EORTC QLQ-STO22, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Stomach 22; EQ-5D-5L VAS, EuroQoL 5-dimension 5-level questionnaire visual analog scale; GHS/QoL, global health status/quality of life; LSM, least squares mean; PRO, patient-reported outcome.
非 KM Figure